Indication: Diffuse Large B-cell Lymphoma
Title: DLBCL/SADAL: A Phase 2b Open-label Study of selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Drug: selinexor

SADAL is an open label, Phase 2b study evaluating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.

Please visit for more information about this study

This trial is for selinexor.


sNDA based on data from SADAL study accepted by FDA with Priority Review granted and PDUFA date set for June 23, 2020

Phase IPhase IIPhase III
Phase I
Phase II
Phase III